Company news
Aquestive Therapeutics, Inc. (NASDAQ:AQST) news
Every Aquestive Therapeutics, Inc. press release and news update in one place — announcements, filings coverage, and company updates for investors.
Press releases & updates
Aquestive Therapeutics to Report Second Quarter 2026 Financial Results and Recent Business Highlights on August 11 and Host Conference Ca...
July 29, 2026
Aquestive Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update
May 13, 2026
Aquestive Therapeutics Completes $150 Million Debt Refinancing with Oaktree
May 12, 2026
Aquestive Therapeutics to Report First Quarter 2026 Financial Results and Recent Business Highlights on May 13 and Host Conference Call o...
May 6, 2026
Aquestive Therapeutics Announces Completion of Type A Meeting with FDA for Anaphylm™ (dibutepinephrine) Sublingual Film
March 30, 2026
Aquestive Therapeutics Announces New Role of Lori J. Braender and Appointment of Thomas A. Zalewski as Chief Legal Officer and Chief Comp...
March 20, 2026
Aquestive Therapeutics Announces Grant of Inducement Award Pursuant to Nasdaq Listing Rule 5635(c)(4)
March 9, 2026
Aquestive Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
March 4, 2026
Aquestive Therapeutics to Participate in Upcoming March Investor Conferences
February 25, 2026
Aquestive Therapeutics to Report Fourth Quarter 2025 Financial Results and Recent Business Highlights on March 4 and Host Conference Call...
February 24, 2026
Aquestive Therapeutics to Participate in Oppenheimer 36th Annual Healthcare Life Sciences Conference
February 23, 2026
Aquestive Therapeutics to Present New Clinical Data on Anaphylm™ (dibutepinephrine) Sublingual Film at the 2026 AAAAI Annual Meeting
February 20, 2026
Aquestive Therapeutics Appoints Internationally Recognized Allergist Dr. Matthew Greenhawt as Chief Medical Officer
February 18, 2026
Aquestive Therapeutics Announces FDA Issuance of Complete Response Letter for Anaphylm™
February 2, 2026
Aquestive Therapeutics Announces Regulatory Development for Anaphylm™ (dibutepinephrine) Sublingual Film and Provides Business Update
January 9, 2026
Aquestive Therapeutics to Participate in the Piper Sandler 37th Annual Healthcare Conference
November 24, 2025
Aquestive Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update
November 5, 2025
Aquestive Therapeutics Announces Leadership Expansion to Support Growth
November 4, 2025
Aquestive Therapeutics to Participate in a Fireside Chat Hosted by Piper Sandler
November 3, 2025
Aquestive Therapeutics to Attend 2025 ACAAI Annual Meeting
October 30, 2025
Aquestive Therapeutics to Report Third Quarter 2025 Financial Results and Recent Business Highlights on November 5 and Host Conference Ca...
October 27, 2025
Aquestive Therapeutics Broadens Patent Estate for Anaphylm™
October 8, 2025
Aquestive Therapeutics Announces that FDA Will Not Require an Advisory Committee Meeting to Discuss New Drug Application for Anaphylm™
September 4, 2025
Aquestive Therapeutics to Participate in Upcoming September Investor Conferences
August 26, 2025
Aquestive Therapeutics Announces $75M Strategic Funding Agreement with RTW to Support the Potential Launch of Anaphylm™ (epinephrine) Sub...
August 14, 2025
Aquestive Therapeutics Announces Pricing of $85 Million Underwritten Offering of Common Stock
August 14, 2025
Aquestive Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update
August 11, 2025
Aquestive Therapeutics to Report Second Quarter 2025 Financial Results and Recent Business Highlights on August 11 and Host Conference Ca...
August 4, 2025
Aquestive Therapeutics Names Sherry Korczynski as Chief Commercial Officer
July 22, 2025
Aquestive Therapeutics Provides International Expansion Update for Anaphylm™ (epinephrine) Sublingual Film
July 15, 2025
Aquestive Therapeutics to Participate in Leerink Partners Therapeutics Forum: I&I and Metabolism
July 7, 2025
Aquestive Therapeutics to Present Positive Data from Pharmacokinetic and Pharmacodynamic Studies of Anaphylm™ (epinephrine) Sublingual Fi...
June 25, 2025
Aquestive Therapeutics Announces FDA Acceptance of New Drug Application and PDUFA Date for Anaphylm™ for the Treatment of Severe Allergic...
June 16, 2025
Aquestive Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update
May 12, 2025
Aquestive Therapeutics to Participate in Citizens Life Sciences Conference
May 5, 2025
Aquestive Therapeutics to Report First Quarter 2025 Financial Results and Recent Business Highlights on May 12 and Host Conference Call o...
May 1, 2025
Aquestive Therapeutics to Participate in Piper Sandler Spring Biopharma Symposium
April 9, 2025
Aquestive Therapeutics Announces Positive Topline PK Results from its Pediatric Study and Completes the NDA Submission for Anaphylm™ (epi...
April 1, 2025
Aquestive Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
March 5, 2025
Aquestive Therapeutics to Participate in Two Upcoming Conferences in March
February 26, 2025
Aquestive Therapeutics to Report Fourth Quarter 2024 Financial Results and Recent Business Highlights on March 5 and Host Conference Call...
February 20, 2025
Aquestive Therapeutics to Present New Findings on Anaphylm™ (Epinephrine Sublingual Film) at the 2025 AAAAI Annual Meeting
February 12, 2025
Aquestive Therapeutics to Participate in Oppenheimer 35th Annual Healthcare Conference
February 4, 2025
Aquestive Therapeutics Provides Business Update and Outlines Key 2025 Objectives
January 13, 2025
Aquestive Therapeutics Receives U.S. FDA Orphan Drug Exclusivity for Libervant® (diazepam) Buccal Film in Pediatric Patients with Seizure...
December 19, 2024
Aquestive Therapeutics Announces Positive FDA Feedback and Reaffirms NDA Submission Guidance for Anaphylm™ (epinephrine) Sublingual Film
December 2, 2024
Aquestive Therapeutics to Participate in Two Upcoming Investor Conferences
November 12, 2024
Aquestive Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update
November 4, 2024
Aquestive Therapeutics to Present Subsequent Analysis of Pivotal Study for Anaphylm™ (epinephrine) Sublingual Film Demonstrating Comparab...
October 25, 2024
Aquestive Therapeutics Announces Positive Topline Results from Oral Allergy Syndrome (OAS) Challenge Study for Anaphylm™ (epinephrine) Su...
October 24, 2024